Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the Guggenheim Nantucket Therapeutics Conference from September 27 to 29, 2022. CEO Raj Mehra will engage in 1x1 investor meetings and a fireside chat on September 28 at 2:45 PM ET, hosted by analyst Yatin Suneja. The company focuses on developing therapies for central nervous system disorders and rare diseases, with projects addressing various conditions including Major Depressive Disorder and amyotrophic lateral sclerosis. A webcast of the fireside chat is available online.

NEW YORK, Sept. 9, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Nantucket Therapeutics Conference, September 27^th to 29^th.

Raj Mehra, Ph.D., Chairman and CEO will hold 1x1 investor meetings and participate in a fireside chat hosted by Senior Biotechnology Analyst Yatin Suneja, on Wednesday, September 28^th at 2:45 PM ET.

Webcast of the fireside chat may be accessed here.   

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2^nd Floor
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-guggenheim-nantucket-therapeutics-conference-301621183.html

SOURCE Seelos Therapeutics, Inc.

FAQ

When is Seelos Therapeutics participating in the Guggenheim Nantucket Therapeutics Conference?

Seelos Therapeutics is participating in the Guggenheim Nantucket Therapeutics Conference from September 27 to 29, 2022.

Who will represent Seelos Therapeutics at the conference?

CEO Raj Mehra will represent Seelos Therapeutics at the conference, holding 1x1 investor meetings and a fireside chat.

What time is the Seelos Therapeutics fireside chat during the conference?

The fireside chat is scheduled for September 28 at 2:45 PM ET.

Where can I access the webcast of the Seelos Therapeutics fireside chat?

The webcast of the fireside chat can be accessed here.

What does Seelos Therapeutics focus on?

Seelos Therapeutics focuses on developing therapies for central nervous system disorders and rare diseases, including conditions like Major Depressive Disorder and amyotrophic lateral sclerosis.